TY - JOUR
T1 - The risk of valvular heart disease in the French Childhood Cancer Survivors’ Study
T2 - Contribution of dose-volume histogram parameters
AU - Chounta, Stefania
AU - Lemler, Sarah
AU - Haddy, Nadia
AU - Fresneau, Brice
AU - Mansouri, Imene
AU - Bentriou, Mahmoud
AU - Demoor-Goldschmidt, Charlotte
AU - Diallo, Ibrahima
AU - Souchard, Vincent
AU - Do, Thi Duyen
AU - Veres, Cristina
AU - Surun, Aurore
AU - Doz, François
AU - Llanas, Damien
AU - Vu-Bezin, Giao
AU - Rubino, Carole
AU - de Vathaire, Florent
AU - Letort, Véronique
AU - Allodji, Rodrigue Setcheou
N1 - Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Background and purpose: Valvular Heart Disease (VHD) is a known complication of childhood cancer after radiotherapy treatment. However, the dose-volume-effect relationships have not been fully explored. Materials and methods: We obtained individual heart Dose Volume Histograms (DVH) for survivors of the French Childhood Cancer Survivors Study (FCCSS) who had received radiotherapy. We calculated the Mean Dose to the Heart (MHD) in Gy, as well as the heart DVH parameters (Vd Gy, which represents the percentage of heart volume receiving at least d Gy), fixing the thresholds to 0.1 Gy, 5 Gy, 20 Gy, and 40 Gy. We analyzed them furtherly in the subpopulation of the cohort that was treated with a dose lower than 5 Gy (V0.1Gy|V5Gy=0%), 20 Gy (V5Gy|V20Gy=0%), and 40 Gy (V20Gy|V40Gy=0%), respectively. We investigated their role in the occurrence of a VHD in this population-based observational cohort study using the Cox proportional hazard model, adjusting for age at cancer diagnosis and chemotherapy exposure. Results: Median follow-up was 30.6 years. Eighty-one patients out of the 7462 (1 %) with complete data experienced a severe VHD (grade ≥ 3). The risk of VHD increased along with the MHD, and it was associated with high doses to the heart (V40Gy < 50 %, hazard ratio (HR) = 7.96, 95 % CI: 4.26–14.88 and V20Gy|V40Gy=0% >50 %, HR = 5.03, 95 % CI: [2.35–10.76]). Doses 5–20 Gy to more than 50 % (V5Gy|V20Gy=0% >50 %) of the heart induced a marginally non-significant estimated risk. We also observed a remarkable risk increase with attained age. Conclusions: Our results provide new insight into the VHD risk that may impact current treatments and long-term follow-up of childhood cancer survivors.
AB - Background and purpose: Valvular Heart Disease (VHD) is a known complication of childhood cancer after radiotherapy treatment. However, the dose-volume-effect relationships have not been fully explored. Materials and methods: We obtained individual heart Dose Volume Histograms (DVH) for survivors of the French Childhood Cancer Survivors Study (FCCSS) who had received radiotherapy. We calculated the Mean Dose to the Heart (MHD) in Gy, as well as the heart DVH parameters (Vd Gy, which represents the percentage of heart volume receiving at least d Gy), fixing the thresholds to 0.1 Gy, 5 Gy, 20 Gy, and 40 Gy. We analyzed them furtherly in the subpopulation of the cohort that was treated with a dose lower than 5 Gy (V0.1Gy|V5Gy=0%), 20 Gy (V5Gy|V20Gy=0%), and 40 Gy (V20Gy|V40Gy=0%), respectively. We investigated their role in the occurrence of a VHD in this population-based observational cohort study using the Cox proportional hazard model, adjusting for age at cancer diagnosis and chemotherapy exposure. Results: Median follow-up was 30.6 years. Eighty-one patients out of the 7462 (1 %) with complete data experienced a severe VHD (grade ≥ 3). The risk of VHD increased along with the MHD, and it was associated with high doses to the heart (V40Gy < 50 %, hazard ratio (HR) = 7.96, 95 % CI: 4.26–14.88 and V20Gy|V40Gy=0% >50 %, HR = 5.03, 95 % CI: [2.35–10.76]). Doses 5–20 Gy to more than 50 % (V5Gy|V20Gy=0% >50 %) of the heart induced a marginally non-significant estimated risk. We also observed a remarkable risk increase with attained age. Conclusions: Our results provide new insight into the VHD risk that may impact current treatments and long-term follow-up of childhood cancer survivors.
KW - Childhood cancer
KW - Dose-volume histogram parameters
KW - Dosimetry
KW - Radiotherapy
KW - Valvular heart disease
KW - Valvulopathy
UR - http://www.scopus.com/inward/record.url?scp=85147286658&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2023.109479
DO - 10.1016/j.radonc.2023.109479
M3 - Article
C2 - 36657724
AN - SCOPUS:85147286658
SN - 0167-8140
VL - 180
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
M1 - 109479
ER -